In a resounding vote of confidence in China's biotechnology sector, leading global pharmaceutical companies are striking multibillion-dollar deals for innovative therapies developed by Chinese firms. These deals mark a pivotal point for China's role in global drug development and have sparked a capital market frenzy.
Caixin
Chinese biotech is having a 'DeepSeek moment'
New class of oncology drugs at heart of many blockbuster deals
Analysts view a current wave of dealmaking as a watershed moment for China's biotech industry and a vital source of capital for domestic firms.
Read Next
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on Caixin
